CA2021316A1 - 11-acyl prostaglandines reductrices de la pression intraoculaire - Google Patents

11-acyl prostaglandines reductrices de la pression intraoculaire

Info

Publication number
CA2021316A1
CA2021316A1 CA2021316A CA2021316A CA2021316A1 CA 2021316 A1 CA2021316 A1 CA 2021316A1 CA 2021316 A CA2021316 A CA 2021316A CA 2021316 A CA2021316 A CA 2021316A CA 2021316 A1 CA2021316 A1 CA 2021316A1
Authority
CA
Canada
Prior art keywords
pressure reducing
intraocular pressure
acyl prostaglandins
prostaglandins
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2021316A
Other languages
English (en)
Other versions
CA2021316C (fr
Inventor
Ming Fai Chan
David Frederick Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2021316A1 publication Critical patent/CA2021316A1/fr
Application granted granted Critical
Publication of CA2021316C publication Critical patent/CA2021316C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002021316A 1989-07-27 1990-07-17 11-acyl prostaglandines reductrices de la pression intraoculaire Expired - Fee Related CA2021316C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38683589A 1989-07-27 1989-07-27
US07/386,835 1989-07-27

Publications (2)

Publication Number Publication Date
CA2021316A1 true CA2021316A1 (fr) 1991-01-28
CA2021316C CA2021316C (fr) 2000-10-24

Family

ID=23527257

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002021316A Expired - Fee Related CA2021316C (fr) 1989-07-27 1990-07-17 11-acyl prostaglandines reductrices de la pression intraoculaire

Country Status (10)

Country Link
US (1) US5446041A (fr)
EP (1) EP0410785B1 (fr)
JP (1) JP3020260B2 (fr)
AT (1) ATE119776T1 (fr)
AU (1) AU635293B2 (fr)
CA (1) CA2021316C (fr)
DE (1) DE69017786T2 (fr)
DK (1) DK0410785T3 (fr)
ES (1) ES2069014T3 (fr)
IE (1) IE67172B1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312842A (en) * 1992-10-30 1994-05-17 Allergan, Inc. Cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or aryl aliphatic derivatives
US5476872A (en) * 1993-10-18 1995-12-19 Allergan, Inc. 1,11-diesters of prostaglandin-F2α having a polar ester group at C-1
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
AU7672096A (en) 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
ES2170956T3 (es) 1996-05-28 2002-08-16 Allergan Sales Inc Derivados 2-alquenilicos de acido ciclopentan(en)oico como agentes terapeuticos en el tratamiento de hipertension ocular.
US6770675B2 (en) 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
US6248783B1 (en) 2000-09-20 2001-06-19 Allergan Sales, Inc. Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
US6291522B1 (en) 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US6376533B1 (en) 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US6586462B2 (en) 2000-10-20 2003-07-01 Allergan, Inc. ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US6531504B2 (en) 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
US6476064B1 (en) 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
US7872045B2 (en) * 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
US20030027853A1 (en) 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
MXPA04004164A (es) 2001-11-05 2004-09-06 Allergan Inc Analogos de omega-cicloalquil 17-heteroaril prostaglandina e2 como agonistas del receptor ep2.
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6875787B2 (en) 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7326716B2 (en) * 2003-06-06 2008-02-05 Allergan, Inc. Treatment of inflammatory bowel disease
BRPI0411057A (pt) * 2003-06-06 2006-07-25 Allergan Inc análogos de prostaglandina e de piperidinila
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US6977260B2 (en) * 2004-01-22 2005-12-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7015243B2 (en) * 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
US7235586B2 (en) * 2003-09-09 2007-06-26 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP1765785B1 (fr) * 2004-07-02 2009-07-08 Allergan, Inc. Analogues de prostaglandine
US7183310B2 (en) * 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
MY150518A (en) * 2008-04-24 2014-01-30 Allergan Inc Substituted gamma lactams as therapeutic agents
US20110136872A1 (en) 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
CN105682645B (zh) 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
US9808531B2 (en) 2015-09-22 2017-11-07 Graybug Vision, Inc. Compounds and compositions for the treatment of ocular disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001306A (en) * 1971-12-30 1977-01-04 The Upjohn Company Prostaglandin F.sub.α 15-monoacrylates
DE2357781A1 (de) * 1972-11-28 1974-05-30 Ciba Geigy Ag Neue 15-substituierte prostansaeurederivate und verfahren zu deren herstellung
US4060540A (en) * 1975-09-18 1977-11-29 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenylmethoxy-1-trans-alkenyl-dialkyl alanates
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
EP0172963A1 (fr) * 1984-08-30 1986-03-05 Ono Pharmaceutical Co., Ltd. Analogues de prostaglandine, leur préparation et composition
US4883819A (en) * 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US4824857A (en) * 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
US4822819A (en) * 1986-11-07 1989-04-18 Alcon Laboratories, Inc. Use of trimoprostil and derivatives in glaucoma therapy
ZA88963B (en) * 1987-02-27 1989-11-29 Allergan Inc Prostaglandins useful for lowering intraocular pressure
DE3871596T3 (de) * 1987-04-03 2000-09-07 Pharmacia & Upjohn Ab, Stockholm Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.
SE8703854D0 (sv) * 1987-10-07 1987-10-07 Pharmacia Ab Prostaglandinderivat for behandling av glaukom eller okuler hypertension

Also Published As

Publication number Publication date
EP0410785B1 (fr) 1995-03-15
DE69017786D1 (de) 1995-04-20
AU635293B2 (en) 1993-03-18
JPH0358931A (ja) 1991-03-14
ES2069014T3 (es) 1995-05-01
JP3020260B2 (ja) 2000-03-15
IE902721A1 (en) 1991-02-27
AU5978690A (en) 1991-01-31
CA2021316C (fr) 2000-10-24
EP0410785A2 (fr) 1991-01-30
US5446041A (en) 1995-08-29
ATE119776T1 (de) 1995-04-15
EP0410785A3 (en) 1991-12-27
IE67172B1 (en) 1996-03-06
DK0410785T3 (da) 1995-06-19
DE69017786T2 (de) 1995-08-03

Similar Documents

Publication Publication Date Title
CA2021316A1 (fr) 11-acyl prostaglandines reductrices de la pression intraoculaire
AU5979290A (en) Intraocular pressure reducing 11, 15-diacyl prostaglandins
IE822618L (en) Treating intraocular pressure
USD318290S (en) Type font
CA2074641A1 (fr) Methode de traitement de l'inflammation oculaire
USD268524S (en) Acupressure instrument for applying rolling pressure to the human body
CA2236582A1 (fr) Analogues tetrahidrofuranniques substitues de prostaglandines utilises comme hypotenseurs oculaires
IE811654L (en) Ophthalmic composition
CA2010860A1 (fr) Filiere d'extrusion sous pression
CA2214575A1 (fr) Comprimes de paroxetine et procede de preparation
USD287476S (en) Tree stand
USD317621S (en) Type font
EP0242580A3 (en) Use of a, b and c prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
CA2083274A1 (fr) Usage pharmacologique de certains derives de cystine
USD317323S (en) Type font
CA2072623A1 (fr) Composition bioadhesive et piece
USD294040S (en) Sign
AU1425388A (en) Prostaglandins useful for lowering intraocular pressure
CA2070672A1 (fr) Compose d'ingredient medical et d'acide hyaluronique, et son procede de production
CA2021180A1 (fr) Procede de preparation de l'hydrochlorure d'.alpha.-aspartyl-l-phenylalanine methyl ester
AU6170490A (en) Reducing the ocular irritancy of anionic shampoos
AU1257895A (en) Antibody to ocular and vaginal surface epithelium
CA2029538A1 (fr) Methode de formage d'une bande anti-implosion a ajustement frette
CA2085807A1 (fr) Couche d'usure en diamant synthetique et procede pour sa realisation
EP0345028A3 (fr) Utilisation d'un inhibiteur de la phosphodiestérase pour le traitement du glaucome

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed